These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 32986682

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I, Santos-García D, Catalán MIJ, Puente V, Valldeoriola F, Grandas F, Mir P, Parra JC, Arbelo JM.
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [Abstract] [Full Text] [Related]

  • 23. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 24. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S, APEX-PD Investigators.
    Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
    Poewe W, Chaudhuri KR, Bergmann L, Antonini A.
    Neurodegener Dis Manag; 2019 Feb; 9(1):39-46. PubMed ID: 30547712
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
    Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.
    CNS Neurol Disord Drug Targets; 2024 Feb; 23(4):476-487. PubMed ID: 36999711
    [Abstract] [Full Text] [Related]

  • 32. Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.
    Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K, Feng G.
    Neurol Ther; 2018 Dec; 7(2):307-319. PubMed ID: 30361858
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
    Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y.
    Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
    Nausieda PA, Hsu A, Elmer L, Gil RA, Spiegel J, Singer C, Khanna S, Rubens R, Kell S, Modi NB, Gupta S.
    J Parkinsons Dis; 2015 Oct; 5(4):837-45. PubMed ID: 26444090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.